News Releases

April 2019

April 15, 2019 4/15/2019 Takeda Announces Top-Ranked Investment Analyst Atsushi Seki to Join Takeda

April 1, 2019 4/1/2019 EMA Accepts Application for a Subcutaneous Formulation of Vedolizumab for Maintenance Therapy in Ulcerative Colitis and Crohn’s Disease

March 2019

March 26, 2019 3/26/2019 Takeda Presents New Data at the Endocrine Society’s 2019 Annual Meeting about the Patient Burden and Long-Term Impact of Chronic Hypoparathyroidism

March 9, 2019 3/9/2019 Vedolizumab Achieves Superior Rates of Clinical Remission vs. Adalimumab in First Ever Head-to-Head Biologic Clinical Study in Ulcerative Colitis

February 2019

February 20, 2019 2/20/2019 Takeda's Sustainability Activities Receive Multiple Accolades by Rigorous ESG Evaluators

February 15, 2019 2/15/2019 Shire's Full Year 2018 Results

February 15, 2019 2/15/2019 Notice Regarding Issue of Hybrid Bonds to replace Senior Short Term Loan (Offering of Subordinated Bonds)

February 11, 2019 2/11/2019 European Commission Approves ADCETRIS with AVD for Adults with Previously Untreated CD30+ Stage IV Hodgkin Lymphoma

February 6, 2019 2/6/2019 Takeda announces results from first-of-its-kind phase IIIb/IV trial PROPEL – a randomized PK-guided prophylaxis study evaluating higher factor VIII levels in hemophilia A– at EAHAD 2019

・For legacy Shire information, click here